English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tropical Medicine and International Health Clinic, Division of Infectious Disease, Ottawa Hospital General Campus Correspondence and reprints: Dr Anne McCarthy, Tropical Medicine and International Health Clinic, Division of Infectious Disease, Ottawa Hospital General Campus, 501 Smyth Road, Ottawa, Ontario K1H 8L6. Telephone 613-737-8184, fax 613-737-8682, e-mail sobhi@ihis.cmh.on.ca T recent emergence of severe acute respiratory syndrome (SARS) is a poignant reminder of our vulnerability to illness originating continents away (1). Canada is an active participant in the global village due to the migration of people and food across multiple borders. This is facilitated by modern transport, which provides the ability to circumnavigate the globe in less than 48 h. At times, these modes of transport can act as vessels to transport pathogens across the miles (2). Fortunately, few globetrotting Canadians will ever experience a life-threatening illness. However, with one million Canadians visiting tropical countries, an annual influx of 250,000 refugees and immigrants, and the increasing tourist traffic from distant lands, there is an expanding need for Canadian health care providers, particularly infectious disease specialists, to consider travel-related and tropical diseases in the differential diagnosis of many common health complaints (3,4). Just as we incorporated routine questions about HIV risk factors into our functional inquiries in the late 1980s, it is past time to pose the question routinely “Have you travelled lately?” when evaluating any patient with fever or flu-like illness. Failure to consider malaria in the febrile patient who has visited a malaria-endemic area may mean the difference between life and death. The good news is that most travel-related illnesses and injuries can be prevented or at least anticipated (5,6). Fatalities in Canadian travellers remain uncommon and are usually cardiac-related or due to trauma, particularly motor vehicle (eg, motorcycle) mishaps (7). Deaths from infectious diseases account for less than 1% of all travel-related deaths. Yet, over the past decade, North American travellers have experienced morbidity and occasional mortality from ailments such as yellow fever (8), malaria (9-11), and dengue (3,4), to name but a few. As well, immigrants to Canada, even many years after migration, can experience the consequences of pathogens acquired in their youth such as tuberculosis, strongyloidiasis, echinococcosis and neurocysticercosis (12). Worldwide, malaria is an important cause of morbidity and mortality. It is also the most important life-threatening infectious disease faced by travellers. In Canada there are 400 to 1000 malaria cases and often one to two deaths reported annually (9,10,13-15). Most malaria deaths can be prevented with early diagnosis and appropriate treatment. What is needed is immediately contemplating the diagnosis, obtaining stat thick and thin blood film results, and reacting appropriately to this medical emergency. It is sobering that many cases of severe malaria are associated with delays in therapy because the diagnosis is not seriously contemplated by the patient, or with delays in therapy at the time of their first contact with the health care system. Over the past two years there have been 24 Canadians who required parenteral quinine therapy for the treatment of Plasmodium falciparum malaria. In 21 of these individuals, the therapy was needed because of severe or complicated disease (16). All these individuals travelled to areas that are well recognized for chloroquine-resistant P falciparum malaria and none received appropriate malaria chemoprophylaxis. As well, 17 patients waited at least 48 h before seeking medical care for their illness. There is little doubt that this delay contributed to the severity of their illness. Appropriate pretravel advice should have ensured effective chemoprophylaxis and counsel on seeking immediate medical attention in the event of a fever or flu-like illness. Uncomplicated P falciparum infection is associated with a 1% case fatality rate, which increases 20-fold with progression to severe disease (for example parasitemia of 5% or evidence of organ dysfunction), even when cared for in a modern intensive care unit! Progression from mild symptoms to complicated disease and even death can occur over as little as 24 to 48 h. As an example, two recent deaths in Canada occurred within days of return from areas of known risk for P falciparum. Both deaths were associated with missed diagnosis, and neither individual received appropriate therapy for their life-threatening disease. Infectious disease physicians are often on the front line (or on the phone line) assessing febrile travellers, obviously the first issue is recognizing that travel has occurred! Once faced with the diagnosis of malaria, immediate, effective therapy is required. Guidance for the treatment of this lifethreatening infection is readily available, including Canadian recommendations by the Committee to Advise on Travel Medicine and Travel (17). Fortunately, most individuals with P falciparum malaria can be treated with oral therapy. Those with severe or complicated disease require parenteral therapy. Parenteral quinine, previously only available through Health Canada’s Special Access Program, is the drug of choice for the treatment of severe and complicated malaria in Canada (17). To facilitate the acquisition of parenteral quinine, the Canadian Malaria Network (previously the Malaria Centres of Excellence) was established to pre-position parenteral quinine stocks across the country for the treatment of individuals with severe or complicated malaria. The main purpose of each of these centres is the pharmacy, which provides 24 h access to this life saving drug. As an additional service, on request, the designated physician for each centre can provide assistance in the management of malaria cases. These distribution centres

Tropical Travel and Life-Threatening Disease: Preventing Malaria Misadventures